DCTH Delcath Systems, Inc. - Common Stock
$16,93
Cena · Sie 18, 2026
Dane fundamentalne na dzień Sie 6, 2026
Zakres 52 tyg.
$8–$17
95% of range
Ocena Analityków
BUY
12 analysts
Cena Docelowa
$24
+42% upside
P/E (TTM)
241.9
ROE
2.5%
Marża Zysku Netto
3.2%
O Delcath Systems, Inc. - Common Stock Przegląd firmy z Wikipedii
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.
Czytaj więcej
Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).
## Phase III melanoma trial enrolling
University of Pittsburgh Medical Center
National Cancer Institute in Bethesda, Maryland
Albany Medical Center in Albany, New York
John Wayne Cancer Center in Santa Monica, California
Moffitt Cancer Center in Tampa, Florida
Morristown Memorial Hospital in Morristown, New Jersey
Providence Cancer Center in Portland, Oregon
St. Luke's Cancer Center of Bethlehem, Pennsylvania
Swedish Medical Center in Englewood, Colorado
University of Maryland Medical Center in Baltimore, Maryland
University of Texas Medical Branch in Galveston, Texas
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
DCTH Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$16.93
Kapitalizacja Rynkowa
$587M
P/E (TTM)
241.9
EPS (TTM)
$0.07
Przychody (TTM)
$85M
Stopa dywidendy
—
ROE
2.5%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$8 – $17
DCTH Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$85M
2016-12-31
→
2025-12-31
EPS
$0.07
2017-12-31
→
2025-12-31
Wolny przepływ pieniężny
$21M
2018-12-31
→
2025-12-31
Marże
3.2%
2022-12-31
→
2025-12-31
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
DCTH
Mediana porównawcza
P/E (TTM)
241.9
32.9
P/S (TTM)
6.9
4.6
P/B
5.3
3.5
Price / FCF (Cena / FCF)
28.0
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
DCTH
Mediana porównawcza
Gross Margin (Marża brutto)
86.2%
66.5%
Operating Margin (Marża Operacyjna)
0.77%
—
Net Profit Margin (Marża Zysku Netto)
3.2%
-9.8%
ROA
2.7%
-8.8%
ROE
2.5%
-15.5%
ROIC
0.46%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
DCTH
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
10.9
4.8
Quick Ratio (Wskaźnik Szybkości)
5.0
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
DCTH
Mediana porównawcza
Revenue YoY (Przychody R/R)
129.1%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
215.3%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
DCTH
Mediana porównawcza
DCTH Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
12 analityków
- Mocne kupno 3 25,0%
- Kup 8 66,7%
- Trzymaj 1 8,3%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
5 analityków · 2026-08-18
Mediana
$22.00
Średnia
$24.00
← Poniżej wszystkich celów
$16.93
Niski
$21.00
Wysoki
$32.00
Średni cel
$22.00
+29,9%
Średnia cel
$24.00
+41,8%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.05%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $0.07 | $-0.09 | 0.16% |
| 31 marca 2026 | $-0.03 | $-0.09 | 0.06% |
| 31 grudnia 2025 | $-0.05 | $-0.06 | 0.01% |
| 30 września 2025 | $0.02 | $0.02 | -0.00% |
| 30 czerwca 2025 | $0.07 | $0.03 | 0.04% |
| 31 marca 2025 | $0.03 | $0.02 | 0.01% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| DCTH | $350M | 144.3 | 129.1% | 3.2% | 2.5% | 86.2% |
| BBNX | $1.35B | -16.8 | 53.9% | -73.0% | -24.9% | 55.4% |
| SSII | — | -94.7 | 105.7% | — | — | — |
| ANGO | $479M | -13.0 | 9.5% | -11.5% | -21.2% | 54.6% |
| TCMD | $651M | 35.4 | 12.5% | 5.8% | 9.2% | 75.9% |
| NPCE | $518M | -23.4 | 25.1% | -21.5% | -111.6% | 77.2% |
| VREX | $498M | -7.0 | 4.1% | -8.3% | -14.0% | 34.4% |
| CLPT | $402M | -15.2 | 17.8% | -69.1% | -106.9% | 61.4% |
| SGHT | $424M | -10.7 | -3.1% | -49.7% | -57.4% | 86.2% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 18
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85M | $37M | $2M | $3M | $4M | · | · | · | $3M | $2M | $2M | $1M | |
| Cost of Revenue | $12M | $6M | $635.0K | $686.0K | $671.0K | $640.0K | $719.0K | $1M | $701.0K | $550.0K | $462.0K | $291.0K | |
| Gross Profit | $73M | $31M | $1M | $2M | $3M | $1M | $861.0K | $2M | $2M | $1M | $1M | $778.0K | |
| R&D Expense | $29M | $14M | $18M | $19M | $14M | $11M | $9M | $20M | $10M | $8M | $6M | $4M | |
| SG&A Expense | $44M | $30M | $22M | $17M | $14M | $11M | $11M | $10M | $10M | $9M | $10M | $16M | |
| Operating Expenses | $73M | $43M | $40M | $36M | $27M | $22M | $21M | $29M | $20M | $18M | $16M | $20M | |
| Operating Income | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | $-18M | $-16M | $-15M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | · | $22M | $14M | $67.0K | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $17.0K | $9.0K | $5.0K | |
| Other Non-op | $-70.0K | $-30.0K | $-59.0K | $30.0K | $68.0K | $154.0K | $2.0K | $51.0K | $-41.0K | $17.0K | $9.0K | $-24.0K | |
| Pretax Income | $4M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Income Tax | $810.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| EPS (Basic) | $0.08 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| EPS (Diluted) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| Shares (Basic) | 35,821,157 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| Shares (Diluted) | 39,919,557 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| EBITDA | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | · | · | $-15M | $-19M |
Bilans 25
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $32M | $13M | $8M | $23M | $29M | $10M | $3M | $4M | $4M | $13M | $20M | |
| Receivables | $12M | $11M | $241.0K | $366.0K | $44.0K | $57.0K | $21.0K | $585.0K | $317.0K | $403.0K | $277.0K | $174.0K | |
| Inventory | $10M | $7M | $3M | $2M | $1M | $855.0K | $654.0K | $858.0K | $1M | $660.0K | $757.0K | $349.0K | |
| Prepaid Expense | $6M | $3M | $1M | $2M | $3M | $3M | $2M | $898.0K | $700.0K | $698.0K | $960.0K | $974.0K | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $222.0K | |
| Current Assets | $120M | $74M | $37M | $16M | $31M | $32M | $13M | $6M | $8M | $34M | $15M | $22M | |
| PP&E (Net) | $3M | $2M | $1M | $1M | $1M | $1M | $735.0K | $925.0K | $1M | $1M | $1M | $2M | |
| PP&E (Gross) | $8M | $7M | $6M | $6M | $6M | $6M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | |
| Total Assets | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Accounts Payable | $3M | $961.0K | $1M | $2M | $638.0K | $2M | $5M | $8M | $4M | $594.0K | $284.0K | $748.0K | |
| Accrued Liabilities | $8M | $5M | $5M | $5M | $4M | $5M | $7M | $8M | $3M | $3M | $2M | $4M | |
| Current Liabilities | $11M | $6M | $16M | $15M | $6M | $10M | $16M | $18M | $8M | $36M | $6M | $5M | |
| Capital Leases | $835.0K | $933.0K | $0 | · | $207.0K | $450.0K | $197.0K | $0 | · | · | · | · | |
| Other Non-current Liabilities | $628.0K | $766.0K | $840.0K | $1M | $207.0K | · | $0 | $628.0K | $395.0K | $604.0K | $820.0K | $1M | |
| Total Liabilities | $12M | $8M | $23M | $24M | $21M | $13M | $21M | $22M | $8M | $37M | $7M | $6M | |
| Long-term Debt | · | $0 | $10M | $16M | · | · | · | · | · | · | · | · | |
| Common Stock | $347.0K | $331.0K | $228.0K | $100.0K | $79.0K | $60.0K | $1.0K | $0 | $2.0K | $0 | $14.0K | $97.0K | |
| Paid-in Capital | $639M | $600M | $521M | $452M | $433M | $417M | $365M | $329M | $326M | $278M | $270M | $265M | |
| Retained Earnings | $-529M | $-532M | $-505M | $-457M | $-421M | $-395M | $-371M | $-344M | $-325M | $-279M | $-261M | $-247M | |
| Treasury Stock | · | · | · | · | · | · | · | $0 | $51.0K | $51.0K | $51.0K | $51.0K | |
| AOCI | $575.0K | $82.0K | $135.0K | $-83.0K | $18.0K | $-104.0K | $28.0K | $50.0K | $42.0K | $-41.0K | $-8.0K | $20.0K | |
| Stockholders' Equity | $111M | $69M | $16M | $-6M | $12M | $22M | $-6M | $-15M | $678.0K | $-1M | $9M | $18M | |
| Liabilities + Equity | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Shares Outstanding | 34,691,671 | 33,061,002 | 22,761,554 | 10,046,571 | 7,906,728 | 5,996,101 | 67,091 | 14,715 | 228,139 | 11,750 | 1,360,239 | 9,708,841 |
Przepływy pieniężne 12
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $23M | $-19M | $-31M | $-25M | $-23M | $-23M | $-24M | $-15M | $-15M | $-14M | $-16M | $-16M | |
| CapEx | $2M | $559.0K | $58.0K | $209.0K | $143.0K | $782.0K | $24.0K | $76.0K | $524.0K | $258.0K | $170.0K | $44.0K | |
| Investing Cash Flow | $-27M | $-981.0K | $-20M | $-209.0K | $-143.0K | $-782.0K | $-24.0K | $-76.0K | $-524.0K | · | · | · | |
| Net Debt Issued | · | $-11M | $-6M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $481.0K | $250.0K | $123.0K | $0 | $2M | $230.0K | $0 | $11M | · | · | · | · | |
| Stock Repurchased | $6M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-6M | $250.0K | $123.0K | · | $2M | $230.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $15M | $39M | $52M | $10M | $21M | $42M | $30M | $13M | $-11M | · | · | · | |
| Net Change in Cash | $11M | $20M | $874.0K | $-15M | $-2M | $19M | $7M | $-2M | $-26M | $-8M | $-8M | $-11M | |
| Taxes Paid | $2M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $21M | $-19M | $-31M | $-25M | $-23M | $-24M | $-24M | $-15M | · | · | $-17M | $-16M |
Rentowność 8
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.2% | 83.4% | 69.2% | 74.8% | · | · | · | · | · | · | 73.6% | 72.8% | |
| Operating Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| Net Margin | 3.2% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | -1625.9% | |
| Pretax Margin | 4.1% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | · | |
| EBITDA Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| ROA | 2.7% | -45.8% | -168.8% | -143.2% | -75.7% | -98.9% | -84.3% | -244.4% | · | · | -74.5% | -57.1% | |
| ROE | 2.5% | -68.2% | -235.5% | 657.5% | -216.7% | -190.6% | 70.5% | 194.1% | · | · | -109.9% | -72.0% | |
| ROIC | 0.46% | -18.1% | -242.0% | 577.8% | -205.3% | -96.5% | 313.2% | · | · | · | -176.8% | · |
Płynność i wypłacalność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 | 3.2 | 0.8 | 0.3 | · | · | 2.3 | 4.8 | |
| Quick Ratio | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 | 2.9 | 0.6 | 0.2 | · | · | 2.0 | 4.5 |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.9 | 0.6 | 0.1 | 0.1 | · | · | · | · | · | · | 0.1 | 0.0 | |
| Inventory Turnover | 1.4 | 1.2 | 0.2 | 0.4 | 0.6 | 0.8 | 1.0 | 1.0 | · | · | 0.8 | 0.5 | |
| Receivables Turnover | 7.5 | 6.7 | 6.8 | 13.3 | · | · | · | · | · | · | 7.7 | 4.1 |
Stopy Wzrostu 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 129.1% | 1701.7% | -24.1% | -23.5% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 215.3% | 118.7% | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $85M | $37M | $2M | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | |
| Net Income TTM | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Market Cap | $350M | $398M | $95M | $28M | $61M | $107M | $1M | $2.01B | · | · | · | · | |
| P/E | 144.3 | -12.9 | -1.4 | -0.9 | -2.2 | -2.1 | -0.1 | -272.2 | · | · | · | · | |
| P/S | 4.1 | 10.7 | 45.9 | 10.5 | 17.2 | 34.8 | 0.5 | 649.3 | · | · | · | · | |
| P/B | 3.2 | 5.8 | 6.0 | -4.9 | 5.1 | 4.9 | -0.2 | -134.2 | · | · | · | · | |
| P / Tangible Book | 3.2 | 5.8 | 6.0 | · | 5.1 | 4.9 | · | · | · | · | · | · | |
| P / Cash Flow | 15.6 | -21.3 | -3.0 | -1.1 | -2.7 | -4.7 | -0.1 | -136.1 | · | · | · | · | |
| P / FCF | 16.7 | -20.7 | -3.0 | -1.1 | -2.7 | -4.5 | -0.1 | -135.4 | · | · | · | · | |
| Earnings Yield | 0.69% | -7.7% | -70.7% | -114.4% | -46.3% | -46.6% | -1613.3% | -0.37% | · | · | · | · |
Rachunek zysków i strat 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $25M | $21M | $21M | $24M | $20M | $15M | $11M | $8M | $3M | $539.0K | $434.0K | $495.0K | $597.0K | $638.0K | $906.0K | |
| Cost of Revenue | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $903.0K | $171.0K | $133.0K | $150.0K | $181.0K | $238.0K | $235.0K | |
| Gross Profit | $26M | $21M | $18M | $18M | $21M | $17M | $13M | $10M | $6M | $2M | $368.0K | $301.0K | $345.0K | $416.0K | $400.0K | $671.0K | |
| R&D Expense | $10M | $10M | $9M | $8M | $7M | $5M | $3M | $4M | $3M | $4M | $5M | $5M | $4M | $5M | $4M | $4M | |
| SG&A Expense | $13M | $13M | $11M | $10M | $11M | $11M | $7M | $7M | $7M | $9M | $7M | $6M | $5M | $4M | $4M | $5M | |
| Operating Expenses | $24M | $23M | $20M | $18M | $18M | $16M | $10M | $11M | $10M | $13M | $12M | $11M | $8M | $9M | $8M | $9M | |
| Operating Income | $2M | $-2M | $-2M | $-388.0K | $3M | $642.0K | $3M | $-1M | $-4M | $-10M | $-11M | $-11M | $-8M | $-8M | $-8M | $-8M | |
| Other Non-op | $-17.0K | $-58.0K | $-7.0K | $-33.0K | $-34.0K | $4.0K | $-53.0K | $35.0K | $10.0K | $-22.0K | $-73.0K | $-5.0K | $6.0K | $13.0K | $27.0K | $26.0K | |
| Pretax Income | $3M | $-908.0K | $-1M | $375.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | · | · | · | · | · | · | |
| Income Tax | $491.0K | $162.0K | $562.0K | $-455.0K | $508.0K | $195.0K | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Income | $3M | $-1M | $-2M | $830.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | $-11M | $-20M | $-7M | $-9M | $-8M | $-9M | |
| EPS (Basic) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.08 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| EPS (Diluted) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.07 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| Shares (Basic) | 35,891,915 | 36,021,210 | -70,991,574 | 36,383,277 | 35,786,813 | 34,642,641 | -53,478,825 | 28,738,307 | 28,364,731 | 24,887,180 | -25,719,196 | 17,863,078 | 12,463,665 | 11,622,384 | -16,732,137 | 9,215,786 | |
| Shares (Diluted) | 39,761,480 | 36,021,210 | -79,911,141 | 40,056,814 | 40,262,764 | 39,511,120 | -57,086,190 | 32,345,672 | 28,364,731 | 24,887,180 | -25,719,196 | 17,863,078 | 12,463,665 | 11,622,384 | -16,732,137 | 9,215,786 | |
| EBITDA | $2M | $-2M | · | $-388.0K | $3M | $642.0K | · | $-1M | $-4M | $-10M | · | $-11M | $-8M | $-8M | · | $-8M |
Bilans 23
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $41M | $43M | $42M | $34M | $13M | $32M | $8M | $15M | $12M | $13M | $40M | $15M | $24M | $8M | $10M | |
| Receivables | $16M | $14M | $12M | $14M | $16M | $14M | $11M | $7M | $4M | $2M | $241.0K | $205.0K | $127.0K | $458.0K | $366.0K | $537.0K | |
| Inventory | $12M | $10M | $10M | $11M | $11M | $7M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | |
| Prepaid Expense | $7M | $7M | $6M | $7M | $6M | $4M | $3M | $1M | $1M | $1M | $1M | $3M | $2M | $2M | $2M | $2M | |
| Current Assets | $131M | $120M | $120M | $121M | $113M | $84M | $74M | $29M | $31M | $34M | $37M | $46M | $19M | $29M | $16M | $18M | |
| PP&E (Net) | $4M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| PP&E (Gross) | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $7M | $7M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| Total Assets | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Accounts Payable | $4M | $3M | $3M | $2M | $5M | $2M | $961.0K | $937.0K | $3M | $1M | $1M | $753.0K | $966.0K | $2M | $2M | $3M | |
| Accrued Liabilities | $9M | $7M | $8M | $6M | $6M | $4M | $5M | $6M | $4M | $4M | $5M | $5M | $6M | $7M | $5M | $5M | |
| Current Liabilities | $13M | $11M | $11M | $8M | $10M | $5M | $6M | $22M | $12M | $13M | $16M | $14M | $11M | $13M | $15M | $14M | |
| Capital Leases | $2M | $815.0K | $835.0K | $855.0K | $877.0K | $906.0K | $933.0K | $963.0K | $989.0K | $1M | $0 | · | · | · | · | · | |
| Other Non-current Liabilities | $327.0K | $615.0K | $628.0K | $582.0K | $578.0K | $896.0K | $766.0K | $563.0K | $632.0K | $962.0K | $840.0K | $1M | $1M | $1M | $1M | $1M | |
| Total Liabilities | $16M | $12M | $12M | $9M | $12M | $7M | $8M | $23M | $30M | $21M | $23M | $23M | $21M | $25M | $24M | $25M | |
| Long-term Debt | · | · | · | · | · | · | · | $2M | $4M | $7M | $10M | · | · | · | $16M | · | |
| Common Stock | $346.0K | $344.0K | $347.0K | $353.0K | $350.0K | $334.0K | $331.0K | $280.0K | $279.0K | $254.0K | $228.0K | $197.0K | $153.0K | $101.0K | $100.0K | $86.0K | |
| Paid-in Capital | $648M | $642M | $639M | $641M | $632M | $610M | $600M | $536M | $534M | $530M | $521M | $519M | $473M | $453M | $452M | $442M | |
| Retained Earnings | $-527M | $-530M | $-529M | $-527M | $-528M | $-530M | $-532M | $-528M | $-530M | $-516M | $-505M | $-494M | $-474M | $-466M | $-457M | $-447M | |
| AOCI | $258.0K | $571.0K | $575.0K | $875.0K | $592.0K | $381.0K | $82.0K | $11.0K | $8.0K | $157.0K | $135.0K | $-59.0K | $-64.0K | $-64.0K | $-83.0K | $-57.0K | |
| Stockholders' Equity | $121M | $113M | $111M | $115M | $105M | $80M | $69M | $9M | $4M | $15M | $16M | $25M | $-242.0K | $-13M | $-6M | $-5M | |
| Liabilities + Equity | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Shares Outstanding | 34,636,252 | 34,465,087 | 34,691,671 | 35,308,939 | 34,955,974 | 33,436,612 | 33,061,002 | 28,019,599 | 27,931,393 | 25,439,319 | 22,761,554 | 19,688,991 | 15,250,469 | 10,046,571 | 10,046,571 | 8,597,682 |
Przepływy pieniężne 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6M | $857.0K | $8M | $5M | $7M | $2M | $-1M | $-4M | $-4M | $-10M | $-8M | $-9M | $-10M | $-4M | $-7M | $-5M | |
| CapEx | $503.0K | $570.0K | $550.0K | $459.0K | $398.0K | $140.0K | $229.0K | $216.0K | $101.0K | $13.0K | $19.0K | $-1.0K | $40.0K | $0 | $0 | $68.0K | |
| Investing Cash Flow | $-504.0K | $-571.0K | $-561.0K | $-466.0K | $-415.0K | $-25M | $-15M | $-697.0K | $10M | $5M | $-20M | $1.0K | $-40.0K | $0 | $0 | $-68.0K | |
| Stock Issued | $0 | $389.0K | $0 | $243.0K | $0 | $238.0K | $0 | $175.0K | $0 | $75.0K | $0 | $76.0K | $0 | $47.0K | $0 | $0 | |
| Stock Repurchased | $11.0K | $3M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $-3M | · | · | · | $238.0K | · | · | · | $75.0K | · | · | · | $47.0K | · | · | |
| Financing Cash Flow | $962.0K | $-2M | $-6M | $3M | $15M | $3M | $40M | $-2M | $-3M | $4M | $1.0K | $35M | $7.0K | $17M | $5M | $5M | |
| Net Change in Cash | $6M | $-2M | $2M | $7M | $22M | $-20M | $24M | $-6M | $3M | $-886.0K | $-28M | $26M | $-10M | $12M | $-2M | $-372.0K | |
| Taxes Paid | · | · | $228.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $287.0K | · | · | · | $2M | · | · | · | $-10M | · | · | · | $-4M | · | · |
Rentowność 8
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.8% | 85.0% | · | 87.2% | 86.3% | 85.6% | · | 85.4% | 80.4% | 71.2% | · | 69.3% | 69.7% | 69.7% | · | · | |
| Operating Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| Net Margin | 9.2% | -4.3% | · | 4.0% | 11.2% | 5.4% | · | 16.6% | -176.9% | -354.0% | · | -4686.6% | -1455.0% | -1507.5% | · | · | |
| Pretax Margin | 10.8% | -3.6% | · | 1.8% | 13.3% | 6.4% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| ROA | 2.1% | -1.0% | · | 1.1% | 3.6% | 1.7% | · | 4.7% | -50.0% | -33.3% | · | -60.0% | -34.2% | -31.1% | · | -31.1% | |
| ROE | 2.4% | -1.1% | · | 1.4% | 4.9% | 2.2% | · | 11.2% | -695.8% | -1439.2% | · | -208.9% | 466.5% | 229.3% | · | -262.5% | |
| ROIC | 1.7% | -1.7% | · | -0.75% | 2.1% | 0.68% | · | · | · | · | · | · | · | · | · | · |
Płynność i wypłacalność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.8 | 11.2 | · | 15.1 | 10.9 | 16.0 | · | 1.3 | 2.6 | 2.5 | · | 3.3 | 1.8 | 2.2 | · | 1.3 | |
| Quick Ratio | 4.8 | 5.2 | · | 6.9 | 4.8 | 5.1 | · | 0.7 | 1.5 | 1.0 | · | 2.9 | 1.3 | 1.8 | · | 0.7 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | · | |
| Inventory Turnover | 0.3 | 0.4 | · | 0.3 | 0.4 | 0.5 | · | 0.4 | 0.3 | 0.3 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.8 | 1.8 | · | 2.0 | 2.5 | 2.6 | · | 3.1 | 4.0 | 3.1 | · | 1.2 | 1.8 | 1.9 | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $99M | $89M | · | $76M | $63M | $42M | · | $23M | $12M | $5M | · | $2M | $3M | $3M | · | · | |
| Net Income TTM | $5M | $4M | · | $6M | $-8M | $-22M | · | $-43M | $-52M | $-48M | · | $-45M | $-35M | $-37M | · | $-35M | |
| Market Cap | $436M | $320M | · | $380M | $475M | $426M | · | $253M | $234M | $121M | · | $80M | $89M | $58M | · | $28M | |
| P/E | 96.8 | 103.1 | · | 59.7 | -42.5 | -15.2 | · | -4.5 | -3.2 | -1.6 | · | -1.2 | -1.6 | -1.4 | · | -0.8 | |
| P/S | 4.4 | 3.6 | · | 5.0 | 7.6 | 10.2 | · | 11.2 | 19.8 | 26.0 | · | 32.8 | 31.8 | 21.6 | · | · | |
| P/B | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | -367.4 | -4.4 | · | -5.2 | |
| P / Tangible Book | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | · | · | · | · | |
| P / Cash Flow | · | 373.2 | · | · | · | 193.2 | · | · | · | -12.7 | · | · | · | -13.5 | · | · | |
| P / FCF | · | 1114.4 | · | · | · | 206.3 | · | · | · | -12.6 | · | · | · | -13.5 | · | · | |
| Earnings Yield | 1.0% | 0.97% | · | 1.7% | -2.4% | -6.6% | · | -22.3% | -31.7% | -61.6% | · | -85.2% | -60.9% | -70.8% | · | -132.5% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $85M | $37M | $2M | $3M | $4M |
| Marża Brutto % | 86.2% | 83.4% | 69.2% | 74.8% | — |
| Marża Operacyjna % | 0.77% | -33.4% | -1849.0% | -1245.0% | — |
| Zysk netto | $3M | $-26M | $-48M | $-37M | $-26M |
| Rozwodniony EPS | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 |
| Wskaźnik Szybkości | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $21M | $-19M | $-31M | $-25M | $-23M |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 140 emitentów · $188.2M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 27 (0 vs poprzedni kw.) | 17 (-3 vs poprzedni kw.) | 40 (+6 vs poprzedni kw.) | 30 (-7 vs poprzedni kw.) | +1.7M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | $41 551 898 | 3 300 389 | 22,08% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $15 375 500 | 1 221 247 | 8,17% | Akcje |
| VANGUARD GROUP INC | $14 879 573 | 1 473 225 | 7,91% | Akcje |
| Propel Bio Management, LLC | $10 971 681 | 871 460 | 5,83% | Akcje |
| STATE STREET CORP | $8 552 135 | 679 280 | 4,55% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $7 923 535 | 629 139 | 4,21% | Akcje |
| ALGERT GLOBAL LLC | $7 311 114 | 580 708 | 3,89% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $7 130 611 | 566 371 | 3,79% | Akcje |
| Divisadero Street Capital Management, LP | $6 292 432 | 499 796 | 3,34% | Akcje |
| ExodusPoint Capital Management, LP | $4 530 940 | 359 884 | 2,41% | Akcje |
| Private Wealth Advisors, LLC | $3 913 765 | 310 863 | 2,08% | Akcje |
| Simplify Asset Management Inc. | $3 333 454 | 264 770 | 1,77% | Akcje |
| BlackRock, Inc. | $3 180 738 | 252 640 | 1,69% | Akcje |
| ADAR1 Capital Management, LLC | $2 825 007 | 224 385 | 1,50% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $2 570 450 | 204 166 | 1,37% | Akcje |
| KENNEDY CAPITAL MANAGEMENT LLC | $2 570 160 | 204 143 | 1,37% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2 435 510 | 193 448 | 1,29% | Akcje |
| Ikarian Capital, LLC | $2 337 548 | 185 667 | 1,24% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $2 290 159 | 181 903 | 1,22% | Akcje |
| CIBC WORLD MARKET INC. | $2 054 789 | 163 208 | 1,09% | Akcje |
| Caption Management, LLC | $1 894 795 | 150 500 | 1,01% | Opcja sprzedaży |
| GOLDMAN SACHS GROUP INC | $1 885 353 | 149 750 | 1,00% | Akcje |
| Lane Generational LLC | $1 884 257 | 149 663 | 1,00% | Akcje |
| HSBC HOLDINGS PLC | $1 705 848 | 135 600 | 0,91% | Akcje |
| Man Group plc | $1 617 752 | 128 495 | 0,86% | Akcje |
| Cubist Systematic Strategies, LLC | $1 562 514 | 145 350 | 0,83% | Akcje |
| Diametric Capital, LP | $1 546 568 | 122 841 | 0,82% | Akcje |
| MORGAN STANLEY | $1 366 506 | 108 539 | 0,73% | Akcje |
| BARCLAYS PLC | $1 354 243 | 107 565 | 0,72% | Akcje |
| Caption Management, LLC | $1 259 000 | 100 000 | 0,67% | Opcja kupna |
| Capital Advisors Wealth Management, LLC | $1 170 870 | 93 000 | 0,62% | Akcje |
| Jefferies Financial Group Inc. | $1 057 308 | 83 980 | 0,56% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1 050 824 | 83 465 | 0,56% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 022 308 | 81 200 | 0,54% | Opcja kupna |
| Stonepine Capital Management, LLC | $1 000 000 | 100 000 | 0,53% | Opcja kupna |
| Caption Management, LLC | $978 243 | 77 700 | 0,52% | Akcje |
| FOX RUN MANAGEMENT, L.L.C. | $776 526 | 61 678 | 0,41% | Akcje |
| Quantbot Technologies LP | $749 860 | 59 560 | 0,40% | Akcje |
| D. E. Shaw & Co., Inc. | $728 885 | 57 894 | 0,39% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $725 864 | 57 654 | 0,39% | Akcje |
| Pale Fire Capital SE | $504 670 | 40 085 | 0,27% | Akcje |
| BANK OF AMERICA CORP /DE/ | $493 931 | 39 232 | 0,26% | Akcje |
| WOLVERINE TRADING, LLC | $479 600 | 44 000 | 0,25% | Opcja kupna |
| RHUMBLINE ADVISERS | $458 822 | 36 444 | 0,24% | Akcje |
| ALPS ADVISORS INC | $441 154 | 35 040 | 0,23% | Akcje |
| EntryPoint Capital, LLC | $437 641 | 34 761 | 0,23% | Akcje |
| SEI INVESTMENTS CO | $394 936 | 31 369 | 0,21% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $378 380 | 30 054 | 0,20% | Akcje |
| Balyasny Asset Management L.P. | $358 412 | 28 468 | 0,19% | Akcje |
| Leonteq Securities AG | $348 730 | 27 699 | 0,19% | Akcje |
| CITADEL ADVISORS LLC | $334 894 | 26 600 | 0,18% | Opcja kupna |
| BOOTHBAY FUND MANAGEMENT, LLC | $319 484 | 25 376 | 0,17% | Akcje |
| Xcelsior Advisor Partners LLC | $318 527 | 25 300 | 0,17% | Akcje |
| Palisades Investment Partners, LLC | $293 007 | 23 273 | 0,16% | Akcje |
| WOLVERINE TRADING, LLC | $269 666 | 24 740 | 0,14% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $239 424 | 25 800 | 0,13% | Akcje |
| MetLife Investment Management, LLC | $235 043 | 18 669 | 0,12% | Akcje |
| Bank of New York Mellon Corp | $234 942 | 18 661 | 0,12% | Akcje |
| WealthPlan Investment Management, LLC | $219 607 | 17 443 | 0,12% | Akcje |
| NOMURA HOLDINGS INC | $210 530 | 16 722 | 0,11% | Akcje |
| WOLVERINE TRADING, LLC | $209 280 | 19 200 | 0,11% | Opcja sprzedaży |
| CITADEL ADVISORS LLC | $202 699 | 16 100 | 0,11% | Opcja sprzedaży |
| CITADEL ADVISORS LLC | $189 391 | 15 043 | 0,10% | Akcje |
| SkyOak Wealth, LLC | $188 850 | 15 000 | 0,10% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $188 850 | 15 000 | 0,10% | Opcja sprzedaży |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $166 729 | 13 243 | 0,09% | Akcje |
| TUDOR INVESTMENT CORP ET AL | $151 609 | 12 042 | 0,08% | Akcje |
| LANARK FINANCIAL, INC. | $150 500 | 11 954 | 0,08% | Akcje |
| CITIGROUP INC | $146 485 | 11 635 | 0,08% | Akcje |
| Invesco Ltd. | $143 790 | 11 421 | 0,08% | Akcje |
| MERCER GLOBAL ADVISORS INC /ADV | $140 744 | 11 179 | 0,07% | Akcje |
| Nuveen, LLC | $138 754 | 11 021 | 0,07% | Akcje |
| Vanguard Global Advisers, LLC | $133 869 | 10 633 | 0,07% | Akcje |
| Schonfeld Strategic Advisors LLC | $131 136 | 10 416 | 0,07% | Akcje |
| LPL Financial LLC | $128 859 | 10 235 | 0,07% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $126 580 | 10 054 | 0,07% | Akcje |
| Police & Firemen's Retirement System of New Jersey | $110 729 | 8 795 | 0,06% | Akcje |
| SHERBROOKE PARK ADVISERS LLC | $109 918 | 10 883 | 0,06% | Akcje |
| Hunting Hill Global Capital, LLC | $104 716 | 11 284 | 0,06% | Akcje |
| MARSHALL WACE, LLP | $84 177 | 6 686 | 0,04% | Akcje |
| FMR LLC | $69 144 | 5 492 | 0,04% | Akcje |
| Private Wealth Advisors, LLC | $62 950 | 5 000 | 0,03% | Opcja kupna |
| NEW YORK STATE COMMON RETIREMENT FUND | $60 432 | 4 800 | 0,03% | Akcje |
| OSAIC HOLDINGS, INC. | $60 254 | 4 786 | 0,03% | Akcje |
| Point72 (DIFC) Ltd | $53 931 | 5 017 | 0,03% | Akcje |
| NORTHERN TRUST CORP | $53 797 | 4 273 | 0,03% | Akcje |
| Persistent Asset Partners Ltd | $52 954 | 4 206 | 0,03% | Akcje |
| Arax Advisory Partners | $51 884 | 4 121 | 0,03% | Akcje |
| IFP Advisors, Inc | $51 657 | 4 103 | 0,03% | Akcje |
| Integrated Wealth Concepts LLC | $48 145 | 3 824 | 0,03% | Akcje |
| Ameritas Investment Partners, Inc. | $38 714 | 3 075 | 0,02% | Akcje |
| Legal & General Group Plc | $34 534 | 2 743 | 0,02% | Akcje |
| CWM, LLC | $29 343 | 3 162 | 0,02% | Akcje |
| Creative Planning | $17 777 | 1 412 | 0,01% | Akcje |
| Tripletail Wealth Management, LLC | $16 632 | 1 260 | 0,01% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $14 950 | 1 611 | 0,01% | Akcje |
| AlphaQuest LLC | $14 473 | 1 433 | 0,01% | Akcje |
| Tower Research Capital LLC (TRC) | $13 711 | 1 089 | 0,01% | Akcje |
| Activest Wealth Management | $12 590 | 1 000 | 0,01% | Akcje |
| Geneos Wealth Management Inc. | $11 621 | 923 | 0,01% | Akcje |
Insiderzy spółki 46 insiderów · 11 dyrektorzy generalni · 16 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jennifer K. Simpson | President and CEO | 8 maja 2020 C | 25 021 | 0 | 0 | $0 |
| Barbra Keck | Chief Financial Officer, Secretary | 8 maja 2020 C | 12 851 | 0 | 0 | $0 |
| Paul M Feinstein | Chief Financial Officer | 30 listopada 2007 A | 3 375 | 0 | 0 | $0 |
| John Purpura | Chief Operating Officer | 13 października 2023 P | 41 526 | 0 | 0 | $0 |
| HERSCHKOWITZ SAMUEL /FA/ | Chief Operating Officer | 29 maja 2007 P | 160 375 | 0 | 0 | $0 |
| Vojo Vukovic | Chief Medical Officer | 12 grudnia 2023 P | 100 000 | 0 | 0 | $0 |
| Sandra Pennell | SVP of Finance, PFO and PAO | 17 listopada 2023 P | 30 000 | 0 | 0 | $0 |
| David L. Hoffman | General Counsel, Chief Compliance Officer and Secretary | 16 listopada 2023 P | 40 000 | 0 | 0 | $0 |
| Kevin Muir | Vice President Commercial Operations | 12 czerwca 2023 A | — | 0 | 0 | $0 |
| Johnny John | Senior Vice President Clinical Development and Medical Affairs | 12 czerwca 2023 A | — | 0 | 0 | $0 |
| Christine Padula | Interim Principal Accounting Officer | 1 września 2021 A | — | 0 | 0 | $0 |
| John Richard Sylvester | Dyrektor | 21 sierpnia 2023 P | 10 550 | 0 | 0 | $0 |
| Aharon Gil | Dyrektor | 12 czerwca 2023 A | 404 000 | 0 | 0 | $0 |
| Steven A J Salamon | Dyrektor | 12 czerwca 2023 A | 440 100 | 0 | 0 | $0 |
| Roger G Stoll PHD | Dyrektor | 12 czerwca 2023 A | 9 309 | 0 | 0 | $0 |
| Rosalind Advisors, Inc. | Dyrektor | 19 kwietnia 2022 P | 433 100 | 0 | 0 | $0 |
| Marco Taglietti | Dyrektor | 8 maja 2020 C | 6 000 | 0 | 0 | $0 |
| William Dodge Rueckert | Dyrektor | 8 maja 2020 C | 6 014 | 0 | 0 | $0 |
| Simon Pedder | Dyrektor | 1 lutego 2019 A | — | 0 | 0 | $0 |
| Laura A Philips | Dyrektor | 23 lipca 2015 P | 205 299 | 0 | 0 | $0 |
| Harold S Koplewicz | Dyrektor | 10 czerwca 2015 A | 45 052 | 0 | 0 | $0 |
| Dennis Langer | Dyrektor | 10 czerwca 2015 A | 20 000 | 0 | 0 | $0 |
| Jonathan Lewis | Dyrektor | 30 czerwca 2008 A | 10 000 | 0 | 0 | $0 |
| Mark Corigliano | Dyrektor | 16 kwietnia 2007 M | 198 176 | 0 | 0 | $0 |
| Daniel Isdaner | Dyrektor | 16 kwietnia 2007 M | 253 668 | 0 | 0 | $0 |
| Elizabeth Czerepak | — | 13 maja 2026 A | — | 0 | 0 | $0 |
| Gerard J Michel | — | 2 marca 2026 P | 342 034 | 2 | 0 | $198 447 |
| Laura Brege | — | 7 lipca 2014 A | 11 678 | 0 | 0 | $0 |
| Tasos Konidaris | — | 7 lipca 2014 A | 11 678 | 0 | 0 | $0 |
| Gabriel Leung | — | 7 lipca 2014 A | 21 485 | 0 | 0 | $0 |
| Douglas G Watson | — | 7 lipca 2014 A | 136 664 | 0 | 0 | $0 |
| Graham G Miao | — | 14 listopada 2013 A | 54 000 | 0 | 0 | $0 |
| Peter J Graham | — | 14 listopada 2013 A | 15 000 | 0 | 0 | $0 |
| William M Appling | — | 15 lipca 2013 A | — | 0 | 0 | $0 |
| Krishna Kandarpa | — | 11 marca 2013 A | 159 000 | 0 | 0 | $0 |
| Harold Mapes | — | 11 marca 2013 A | 17 000 | 0 | 0 | $0 |
| Eamonn P Hobbs | — | 11 marca 2013 A | 162 000 | 0 | 0 | $0 |
| Agustin V Gago | — | 11 marca 2013 A | 80 944 | 0 | 0 | $0 |
| Robert Ladd | — | 15 czerwca 2012 A | 69 534 | 0 | 0 | $0 |
| David Mcdonald | — | 10 marca 2011 A | 47 706 | 0 | 0 | $0 |
| Pamela Reilly Contag | — | 1 grudnia 2010 A | 8 507 | 0 | 0 | $0 |
| Richard Taney | — | 10 grudnia 2009 A | 211 485 | 0 | 0 | $0 |
| Jason Andrew Rifkin | — | 12 października 2009 A | — | 0 | 0 | $0 |
| KOLY M S /FA/ | — | 26 stycznia 2007 X | 775 360 | 0 | 0 | $0 |
| Victor Nevins | — | 12 października 2006 M | 180 007 | 0 | 0 | $0 |
| VENKOL TRUST | — | 10 listopada 2004 J | 892 649 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 17 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc., SALAMON STEVEN A J, Aharon Gil, Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P. ×15 zgłoszenia | 10 lutego 2026 | 9,90% | Aneks | — | SEC |
| Niezgłoszona osoba raportująca | 16 grudnia 2022 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 27 lipca 2022 | — | Pierwotne zgłoszenie | — | SEC |
| Laddcap Value Partners LP S.S. or, Laddcap Value Associates LLC S.S. or, Laddcap Value Advisors LLC S.S. or, Robert Ladd S.S. or ×2 zgłoszenia | 2 sierpnia 2010 | — | Pierwotne zgłoszenie | — | SEC |
| Robert Ladd | 18 października 2006 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 28 lipca 2006 | — | Pierwotne zgłoszenie | Kampania zarządu | SEC |
| Niezgłoszona osoba raportująca | 11 lipca 2006 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 14 czerwca 2006 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 8 czerwca 2006 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 24 maja 2006 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 28 kwietnia 2006 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 10 stycznia 2006 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 6 stycznia 2006 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 14 grudnia 2005 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 10 listopada 2005 | — | Pierwotne zgłoszenie | Kampania zarządu | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 22 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 0,24% | 35 814 NS | 31 maja 2026 | N-PORT |
| IWC · iShares Trust | 0,10% | 97 850 SH | 8 sierpnia 2026 | Dziennie |
| GSSC · Goldman Sachs ETF Trust | 0,04% | 35 321 NS | 31 maja 2026 | N-PORT |
| IWN · iShares Trust | 0,02% | 227 534 SH | 8 sierpnia 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 21 358 SH | 8 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | 0,01% | 741 852 SH | 8 sierpnia 2026 | Dziennie |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,01% | 2 388 SH | 8 sierpnia 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 165 177 SH | 8 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,01% | 13 080 NS | 30 kwietnia 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,01% | 22 609 NS | 31 maja 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 1 420 NS | 31 maja 2026 | N-PORT |
| UWM · ProShares Trust | 0,00% | 1 111 NS | 31 maja 2026 | N-PORT |
| IWO · iShares Trust | 0,00% | 38 572 SH | 8 sierpnia 2026 | Dziennie |
| URTY · ProShares Trust | 0,00% | 1 122 NS | 31 maja 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 1 638 NS | 31 maja 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 28 NS | 31 maja 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,00% | 19 222 NS | 30 kwietnia 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 43 750 SH | 8 sierpnia 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 304 809 SH | 8 sierpnia 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 889 410 SH | 8 sierpnia 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 4 438 SH | 8 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2 475 SH | 8 sierpnia 2026 | Dziennie |